U.S. President Donald Trump said Thursday that the U.S. Food and Drug Administration (FDA) has approved the use of chloroquine for patients suffering from recent health incidents. Chloroquine is a cheap antimalarial drug that has been used clinically for decades and is most marketed under the name Nivaquine or Plaquenil.
Didier Raoult, a professor at the University Hospital Institute of Marseille, which conducts the treatment of chloroquine, said Monday that tests showed that chloroquine was effective, with three-quarters of patients taking the drug within six days.
However, FDA director Harn said the drug still needs clinical trials. “The president has instructed us to study the drug carefully to determine whether it can be extended to the scope of the drug and to actually understand whether it is good for the patient,” he said. “
German drugmaker Bayer (BAYRY. THE UNITED STATES ANNOUNCED THURSDAY THAT IT HAS DONATED 3 MILLION CHLOROQUINE PRODUCTS, RESOCHIN, AND IS SEEKING EMERGENCY LICENSES FOR THE DRUG, WHICH HAS NOT YET BEEN APPROVED FOR USE IN THE UNITED STATES. Mylan Pharmaceuticals (MYL. US) said it had resumed production of hydroxychloroquine sulfate tablets.
Mr. Trump also said that Giled Science (GILD. U.S.-OWNED REDSEY HAS BEEN “DE FACTO” APPROVED AS A PRESCRIPTION DRUG.
As of Thursday’s close, Bayer (BAYRY. US) closed up 0.97 per cent, while Mylan Pharmaceuticals (MYL. US) closed up 4.87 per cent, with Gilead Sciences (GILD. US) closed down 1.1 percent.